What one share of Lunai Bioworks holds
GEDi Cube B.V. ("GEDi Cube"), acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and subsequent deconsolidation, the Company continued pursuing its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics, which had been acquired prior to the bankruptcy.
Lunai Bioworks’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$1.06 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.57 |
| Cash and investments | $0.37 |
| Debt | $0.08 |
| Book value | −$1.96 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$86.27 | — | — | — | −$9.63 |
| 2026 | $0.02 | −$1.06 | $0.00 | −$1.57 | — | −$1.96 |
Common questions about Lunai Bioworks
How much does one share of Lunai Bioworks earn?
Over its latest fiscal year, Lunai Bioworks lost $1.06 for each share on $0.02 of sales.
Does Lunai Bioworks pay a dividend?
Lunai Bioworks didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Lunai Bioworks’s book value per share?
Lunai Bioworks’s book value is negative (−$1.96 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Lunai Bioworks have?
Each share of Lunai Bioworks has $0.37 of cash and investments and $0.08 of debt, as of June 30, 2026.
What is Lunai Bioworks’s free cash flow per share?
−$1.57 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.